Page 70 - Read Online
P. 70
Page 14 of 16 Karolak et al. J Cancer Metastasis Treat 2021;7:15 https://dx.doi.org/10.20517/2394-4722.2021.05
Conflicts of interest
All authors declare that there are no conflicts of interest.
Ethical approval and consent to participate
Not applicable.
Consent for publication
Not applicable.
Copyright
© The Author(s) 2021.
REFERENCES
1. Marchesi I, Fiorentino FP, Rizzolio F, Giordano A, Bagella L. The ablation of EZH2 uncovers its crucial role in rhabdomyosarcoma
formation. Cell Cycle 2012;11:3828-36. DOI PubMed PMC
2. Vella S, Pomella S, Leoncini PP, et al. MicroRNA-101 is repressed by EZH2 and its restoration inhibits tumorigenic features in
embryonal rhabdomyosarcoma. Clin Epigenetics 2015;7:82. DOI PubMed PMC
3. Shen JK, Cote GM, Gao Y, et al. Targeting EZH2-mediated methylation of H3K27 inhibits proliferation and migration of Synovial
Sarcoma in vitro. Sci Rep 2016;6:25239. DOI PubMed PMC
4. Kawano S, Grassian AR, Tsuda M, et al. Preclinical Evidence of Anti-Tumor Activity Induced by EZH2 Inhibition in Human Models
of Synovial Sarcoma. PLoS ONE 2016;11:e0158888. DOI PubMed PMC
5. Zhang P, Garnett J, Creighton CJ, et al. EZH2-miR-30d-KPNB1 pathway regulates malignant peripheral nerve sheath tumour cell
survival and tumourigenesis. J Pathol 2014;232:308-18. DOI PubMed PMC
6. Knutson SK, Warholic NM, Wigle TJ, et al. Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition
of methyltransferase EZH2. Proc Natl Acad Sci U S A 2013;110:7922-7. DOI PubMed PMC
7. Moreno N, Kerl K. Preclinical evaluation of combined targeted approaches in malignant rhabdoid tumors. Anticancer Res
2016;36:3883-7. PubMed
8. Sun X, Guo W, Shen JK, Mankin HJ, Hornicek FJ, Duan Z. Rhabdomyosarcoma: Advances in Molecular and Cellular Biology.
Sarcoma 2015;2015:232010. DOI PubMed PMC
9. Shi Y, Wang XX, Zhuang YW, Jiang Y, Melcher K, Xu HE. Structure of the PRC2 complex and application to drug discovery. Acta
Pharmacol Sin 2017;38:963-76. DOI PubMed PMC
10. Ciarapica R, Miele L, Giordano A, Locatelli F, Rota R. Enhancer of zeste homolog 2 (EZH2) in pediatric soft tissue sarcomas: first
implications. BMC Med 2011;9:63. DOI PubMed PMC
11. Ezhkova E, Pasolli HA, Parker JS, et al. Ezh2 orchestrates gene expression for the stepwise differentiation of tissue-specific stem cells.
Cell 2009;136:1122-35. DOI PubMed PMC
12. Pereira JD, Sansom SN, Smith J, Dobenecker MW, Tarakhovsky A, Livesey FJ. Ezh2, the histone methyltransferase of PRC2,
regulates the balance between self-renewal and differentiation in the cerebral cortex. Proc Natl Acad Sci U S A 2010;107:15957-62.
DOI PubMed PMC
13. Zhang Q, Han Q, Zi J, et al. Mutations in EZH2 are associated with poor prognosis for patients with myeloid neoplasms. Genes Dis
2019;6:276-81. DOI PubMed PMC
14. Morschhauser F, Tilly H, Chaidos A, et al. Phase 2 Multicenter Study of Tazemetostat, an EZH2 Inhibitor, in Patients with Relapsed or
Refractory Follicular Lymphoma. Blood 2019;134:123. DOI
15. Je EM, An CH, Yoo NJ, Lee SH. Mutational analysis of PIK3CA, JAK2, BRAF, FOXL2, IDH1, AKT1 and EZH2 oncogenes in
sarcomas. APMIS 2012;120:635-9. DOI PubMed
16. Deng P, Chen QM, Hong C, Wang CY. Histone methyltransferases and demethylases: regulators in balancing osteogenic and
adipogenic differentiation of mesenchymal stem cells. Int J Oral Sci 2015;7:197-204. DOI PubMed PMC
17. Dudakovic A, Camilleri ET, Xu F, et al. Epigenetic Control of Skeletal Development by the Histone Methyltransferase Ezh2. J Biol
Chem 2015;290:27604-17. DOI PubMed PMC
18. Hemming S, Cakouros D, Isenmann S, et al. EZH2 and KDM6A act as an epigenetic switch to regulate mesenchymal stem cell lineage
specification. Stem Cells 2014;32:802-15. DOI PubMed
19. Yu Y, Deng P, Yu B, et al. Inhibition of EZH2 Promotes Human Embryonic Stem Cell Differentiation into Mesoderm by Reducing
H3K27me3. Stem Cell Reports 2017;9:752-61. DOI PubMed PMC
20. Zhang N, Zeng Z, Li S, Wang F, Huang P. High expression of EZH2 as a marker for the differential diagnosis of malignant and benign
myogenic tumors. Sci Rep 2018;8:12331. DOI PubMed PMC
21. Wilson BG, Wang X, Shen X, et al. Epigenetic antagonism between polycomb and SWI/SNF complexes during oncogenic
transformation. Cancer Cell 2010;18:316-28. DOI PubMed PMC
22. Kadoch C, Copeland RA, Keilhack H. PRC2 and SWI/SNF Chromatin Remodeling Complexes in Health and Disease. Biochemistry
2016;55:1600-14. DOI PubMed